XTANDI® (enzalutamide) capsules

Legal notice

Astellas Pharma US, Inc. (Astellas) and Medivation, Inc. offer products and services to diagnose, prevent and treat disease. Their prescription medicines for use by healthcare professionals are regulated by government agencies in each of the countries in which they do business, such as the Food and Drug Administration in the United States (U.S.) or the Committee on Safety of Medicine in the United Kingdom. These regulations often restrict the prescribing information that can be disclosed to the public so that you need to consult with your healthcare professional. You may also need to visit other healthcare web sites to find out more about prescription products.

This web site has been developed as a service of Astellas and Medivation, Inc. Like any other service, in spite of our best efforts the information in this web site may become out of date over time. Nothing on this web site should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important that you rely only on the advice of a healthcare professional to advise you on your specific situation. Astellas and Medivation, Inc. accept no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this web site. These materials are provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

This U.S.-based web site may link you to other web sites on the internet, including the web sites for Astellas and Medivation, Inc. affiliates in other countries. Neither Astellas nor Medivation, Inc. take responsibility for information found on third-party web sites outside its control. While Astellas and Medivation, Inc. attempt to provide links only to third-party web sites that comply with all applicable laws and regulations and Astellas or Medivation, Inc. standards, please understand that the content on these third-party web sites is subject to change without notice to Astellas or Medivation, Inc. Neither Astellas nor Medivation, Inc. therefore can be responsible for, and accept no liability for, any information or opinion contained in any third-party web site.

Nothing on this web site constitutes an invitation or offer to invest or deal in the securities or ADRs of Astellas or Medivation, Inc. In particular, actual results and developments may be materially different from any forecast, opinion or expectation expressed on this web site and the past performance of the price of securities must not be relied on as a guide to their future performance.

COPYRIGHT AND INTELLECTUAL PROPERTY

Astellas and Medivation, Inc. hereby authorize you to copy materials published on this web site for non-commercial use only, provided any copy of these materials which you make shall retain all copyright and other proprietary notices and any disclaimer contained thereon and on this web site.

Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Astellas Pharma US, Inc. or Medivation or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Astellas copyright or Medivation copyright.

Trademarks and service marks owned by or licensed to Astellas or Medivation, Inc. are presented as italicized typefaces, such as Seretide or Tums. British and American spellings are used, depending on the author or source of the information. Astellas and Medivation, Inc. claim no ownership in, nor any affiliation with, any third-party trademarks appearing in this web site. Such third-party trademarks are used only to identify the products and services of their respective owners, and no sponsorship or endorsement on the part of Astellas or Medivation, Inc. should be inferred from the use of these marks.

Should any viewer of a Astellas or a Medivation, Inc. published document respond with information including feedback data such as questions, comments, suggestions, or the like regarding the content of any such Astellas or Medivation, Inc. material, such information shall be deemed to be non-confidential and we shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. We shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.

Indication

XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel.

Important Safety Information

Contraindications XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action. XTANDI is not indicated for use in women. XTANDI is contraindicated in women who are or may become pregnant.

Warnings and Precautions In the randomized clinical trial, seizure occurred in 0.9% of patients on XTANDI. No patients on the placebo arm experienced seizure. Patients experiencing a seizure were permanently discontinued from therapy. All seizures resolved. Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.

Adverse Reactions The most common adverse drug reactions (≥ 5%) reported in patients receiving XTANDI in the randomized clinical trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% grade 3-4) and in 6% of patients on placebo (no grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of XTANDI

patients and 2% of patients on placebo. One percent of XTANDI patients compared to 0.3% of patients on placebo died from infections or sepsis. Falls or injuries related to falls occurred in 4.6% of XTANDI patients vs 1.3% of patients on placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in XTANDI patients and included non-pathologic fractures, joint injuries, and hematomas. Grade 1 or 2 hallucinations occurred in 1.6% of XTANDI patients and 0.3% of patients on placebo, with the majority on opioid-containing medications at the time of the event.

Drug Interactions: Effect of Other Drugs on XTANDI Administration of strong CYP2C8 inhibitors can increase the plasma exposure to XTANDI. Coadministration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If coadministration of XTANDI cannot be avoided, reduce the dose of XTANDI. Coadministration of XTANDI with strong or moderate CYP3A4 and CYP2C8 inducers can alter the plasma exposure of XTANDI and should be avoided if possible. Effect of XTANDI on Other Drugs XTANDI is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is coadministered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

Please see Full Prescribing Information for complete safety information.

Legal notice

COPYRIGHT AND INTELLECTUAL PROPERTY

Indication

Important Safety Information

Reference

Indication

Important Safety Information

Reference